Kite Pharma Garners $50,000,000 New Round

  • Feed Type
  • Date
    4/28/2014
  • Company Name
    Kite Pharma
  • Mailing Address
    2225 Colorado Avenue Santa Monica, CA 90404 USA
  • Company Description
    Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient’s own immune system to fight tumor cells.
  • Website
    http://www.kitepharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $50,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Kite expects to use proceeds of the financing to advance its programs developing novel cancer immunotherapy products. Kite’s lead investigational therapy is an autologous eACT product that targets CD19 expression on B cell malignancies, including diffuse large B cell lymphoma (DLBCL). Additional programs will target a number of both hematological malignancies and solid tumors.
  • M&A Terms
  • Venture Investor

Trending on Xconomy